Literature DB >> 8588233

Cyclosporine A: clinical experience and therapeutic drug monitoring.

A Lindholm1.   

Abstract

This article updates current studies on the concentration-effect relationship for cyclosporine A using specific analytical methodology in whole blood. Most of the existing documentation concerns renal transplantation. Trough level monitoring is recommended as the standard monitoring technique. However, there is a need to compare trough level monitoring with monitoring of the area-under-the-concentration-versus-time curve in prospective controlled trials. Further, there is a continuous need to update the concentration-effect relationship when introducing new immunosuppressive drug regimens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8588233     DOI: 10.1097/00007691-199512000-00015

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients.

Authors:  M Büchler; P Leibenguth; C Le Guellec; A Carayon; H Watier; F Odoul; E Autret-Leca; Y Lebranchu; G Paintaud
Journal:  Eur J Clin Pharmacol       Date:  2004-11-20       Impact factor: 2.953

Review 2.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.

Authors:  Kenneth W Renton; John F S Crocker; Heather McLellan; Philip D Acott
Journal:  Eur J Clin Pharmacol       Date:  2004-07-01       Impact factor: 2.953

4.  Clinical Risk Scoring Models for Prediction of Acute Kidney Injury after Living Donor Liver Transplantation: A Retrospective Observational Study.

Authors:  Mi Hye Park; Haeng Seon Shim; Won Ho Kim; Hyo-Jin Kim; Dong Joon Kim; Seong-Ho Lee; Chung Su Kim; Mi Sook Gwak; Gaab Soo Kim
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.